{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:00:42Z","timestamp":1786716042722,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11914-021-00687-7","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T01:05:29Z","timestamp":1625274329000},"page":"417-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Bisphosphonates, Bone and Joint Pain"],"prefix":"10.1007","volume":"19","author":[{"given":"Michel","family":"Villatoro-Villar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-550X","authenticated-orcid":false,"given":"C. Kent","family":"Kwoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"key":"687_CR1","doi-asserted-by":"publisher","first-page":"h3783","DOI":"10.1136\/bmj.h3783","volume":"351","author":"S Maraka","year":"2015","unstructured":"Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ. 2015;351:h3783.","journal-title":"BMJ."},{"issue":"9","key":"687_CR2","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032\u201345.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"687_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jbspin.2006.06.005","volume":"74","author":"A Corrado","year":"2007","unstructured":"Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine. 2007;74(1):32\u20138.","journal-title":"Joint Bone Spine"},{"key":"687_CR4","doi-asserted-by":"crossref","unstructured":"Chen LR, Ko NY, Chen KH. Medical treatment for osteoporosis: From Molecular to Clinical Opinions. Int J Mol Sci. 2019;20(9).","DOI":"10.3390\/ijms20092213"},{"issue":"1","key":"687_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","volume":"49","author":"S Cremers","year":"2011","unstructured":"Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011;49(1):42\u20139.","journal-title":"Bone."},{"key":"687_CR6","doi-asserted-by":"crossref","unstructured":"Stapleton M, Sawamoto K, Almeciga-Diaz CJ, Mackenzie WG, Mason RW, Orii T, et al. Development of bone targeting drugs. Int J Mol Sci. 2017;18(7).","DOI":"10.3390\/ijms18071345"},{"issue":"1","key":"687_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1248\/bpb.b16-00521","volume":"40","author":"K Shima","year":"2017","unstructured":"\u2022\u2022 Shima K, Tsuchiya M, Oizumi T, Takano-Yamamoto T, Sugawara S, Endo Y. Inflammatory effects of nitrogen-containing bisphosphonates (N-BPs): modulation by non-N-BPs. Biol Pharm Bull. 2017;40(1):25\u201333 Provides information that mindronate, zoledronic acid, Ibandronate, pamidronate, alendronate, and risedronate have an inflammatory effect (in mice models) and the non-nitrogen-bisphosphonates etidronate, clodronate and the SLC20\/34 can reduce or prevent the inflammatory effect of the other nitrogen-bisphosphonates. They also theorize that Etidronate could potentially reduce the risk of BP-related osteonecrosis of the jaw and Clo could be useful as a combination drug with an N-BP for preventing the inflammatory\/necrotic side effects without affecting potent anti-bone-resorptive effects.","journal-title":"Biol Pharm Bull"},{"key":"687_CR8","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research. FDA Approved Drug Products. [Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm."},{"key":"687_CR9","unstructured":"European Medicines Agency (EMA). Bisphosphonates. Available from: https:\/\/www.ema.europa.eu\/en."},{"issue":"1","key":"687_CR10","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1186\/s40064-016-3359-y","volume":"5","author":"RL Xing","year":"2016","unstructured":"\u2022\u2022 Xing RL, Zhao LR, Wang PM. Bisphosphonates therapy for osteoarthritis: a meta-analysis of randomized controlled trials. Springerplus. 2016;5(1):1704 Reviews the effect of bisphosphonates for patients with OA and suggest that they are effective in relieving pain and accelerating funtional recovery.","journal-title":"Springerplus"},{"key":"687_CR11","doi-asserted-by":"crossref","unstructured":"Tzschentke TM. Pharmacology of bisphosphonates in pain. Br J Pharmacol. 2019.","DOI":"10.1111\/bph.14799"},{"issue":"11","key":"687_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrrheum.2012.130","volume":"8","author":"DB Burr","year":"2012","unstructured":"Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat Rev Rheumatol. 2012;8(11):665\u201373.","journal-title":"Nat Rev Rheumatol"},{"key":"687_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1749-6632.2009.05240.x","volume":"1192","author":"MB Goldring","year":"2010","unstructured":"Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci. 2010;1192:230\u20137.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"687_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mcna.2008.09.006","volume":"93","author":"SR Goldring","year":"2009","unstructured":"Goldring SR. Role of bone in osteoarthritis pathogenesis. Med Clin North Am. 2009;93(1):25\u201335 xv.","journal-title":"Med Clin North Am"},{"issue":"5","key":"687_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/ar3448","volume":"13","author":"DA Walsh","year":"2011","unstructured":"Walsh DA, Chapman V. Bisphosphonates for osteoarthritis. Arthritis Research & Therapy. 2011;13(5):128.","journal-title":"Arthritis Research & Therapy"},{"issue":"2","key":"687_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.joca.2017.11.013","volume":"26","author":"EE Vaysbrot","year":"2018","unstructured":"\u2022\u2022 Vaysbrot EE, Osani MC, Musetti MC, McAlindon TE, Bannuru RR. Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2018;26(2):154\u201364 Provides information that bisphosphonates don\u2019t seem to provide symptomatic relief or defer radiographic progression in patients with knee OA.","journal-title":"Osteoarthr Cartil"},{"key":"687_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12931-015-0208-4","volume":"16","author":"LM Pinto","year":"2015","unstructured":"Pinto LM, Alghamdi M, Benedetti A, Zaihra T, Landry T, Bourbeau J. Derivation and validation of clinical phenotypes for COPD: a systematic review. Respir Res. 2015;16:50.","journal-title":"Respir Res"},{"issue":"2","key":"687_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.joca.2016.09.025","volume":"25","author":"NE Lane","year":"2017","unstructured":"Lane NE, Shidara K, Wise BL. Osteoarthritis year in review 2016: clinical. Osteoarthr Cartil. 2017;25(2):209\u201315.","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"687_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/ar3299","volume":"13","author":"SM Bierma-Zeinstra","year":"2011","unstructured":"Bierma-Zeinstra SM, Verhagen AP. Osteoarthritis subpopulations and implications for clinical trial design. Arthritis research & therapy. 2011;13(2):213.","journal-title":"Arthritis research & therapy"},{"issue":"1","key":"687_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12891-016-1286-2","volume":"17","author":"A Dell\u2019Isola","year":"2016","unstructured":"Dell\u2019Isola A, Allan R, Smith SL, Marreiros SS, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016;17(1):425.","journal-title":"BMC Musculoskelet Disord"},{"issue":"12","key":"687_CR21","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.joca.2017.08.009","volume":"25","author":"LA Deveza","year":"2017","unstructured":"\u2022\u2022 Deveza LA, Melo L, Yamato TP, Mills K, Ravi V, Hunter DJ. Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review. Osteoarthritis and cartilage \/ OARS. Osteoarthritis Research Society. 2017;25(12):1926\u201341 Provides information that particular subgroups of patients with knee osteoarthritis maybe more likely to benefit from bisphosphonate therapy than others.","journal-title":"Osteoarthritis Research Society"},{"issue":"5","key":"687_CR22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.joca.2010.09.013","volume":"19","author":"NE Lane","year":"2011","unstructured":"Lane NE, Brandt K, Hawker G, Peeva E, Schreyer E, Tsuji W, et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthr Cartil. 2011;19(5):478\u201382.","journal-title":"Osteoarthr Cartil"},{"issue":"4","key":"687_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.joca.2007.12.015","volume":"16","author":"GA Hawker","year":"2008","unstructured":"Hawker GA, Davis AM, French MR, Cibere J, Jordan JM, March L, et al. Development and preliminary psychometric testing of a new OA pain measure--an OARSI\/OMERACT initiative. Osteoarthritis and cartilage \/ OARS, Osteoarthritis Research Society. 2008;16(4):409\u201314.","journal-title":"Osteoarthritis and cartilage \/ OARS, Osteoarthritis Research Society"},{"issue":"2","key":"687_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.rdc.2008.04.003","volume":"34","author":"S Marchand","year":"2008","unstructured":"Marchand S. The physiology of pain mechanisms: from the periphery to the brain. Rheum Dis Clin N Am. 2008;34(2):285\u2013309.","journal-title":"Rheum Dis Clin N Am"},{"issue":"9","key":"687_CR25","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.joca.2013.05.017","volume":"21","author":"DJ Hunter","year":"2013","unstructured":"Hunter DJ, Guermazi A, Roemer F, Zhang Y, Neogi T. Structural correlates of pain in joints with osteoarthritis. Osteoarthritis and cartilage \/ OARS, Osteoarthritis Research Society. 2013;21(9):1170\u20138.","journal-title":"Osteoarthritis and cartilage \/ OARS, Osteoarthritis Research Society"},{"issue":"10","key":"687_CR26","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1002\/art.34594","volume":"64","author":"MK Javaid","year":"2012","unstructured":"Javaid MK, Kiran A, Guermazi A, Kwoh CK, Zaim S, Carbone L, et al. Individual magnetic resonance imaging and radiographic features of knee osteoarthritis in subjects with unilateral knee pain: the health, aging, and body composition study. Arthritis Rheum. 2012;64(10):3246\u201355.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"687_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176833","volume":"12","author":"EC Sayre","year":"2017","unstructured":"Sayre EC, Guermazi A, Esdaile JM, Kopec JA, Singer J, Thorne A, et al. Associations between MRI features versus knee pain severity and progression: data from the Vancouver Longitudinal Study of Early Knee Osteoarthritis. PLoS One. 2017;12(5):e0176833.","journal-title":"PLoS One"},{"issue":"5","key":"687_CR28","doi-asserted-by":"publisher","first-page":"R112","DOI":"10.1186\/ar4292","volume":"15","author":"JB Driban","year":"2013","unstructured":"Driban JB, Price LL, Lo GH, Pang J, Hunter DJ, Miller E, et al. Evaluation of bone marrow lesion volume as a knee osteoarthritis biomarker - longitudinal relationships with pain and structural changes: data from the Osteoarthritis Initiative. Arthritis Research & Therapy. 2013;15(5):R112.","journal-title":"Arthritis Research & Therapy"},{"issue":"3","key":"687_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/art.30148","volume":"63","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Nevitt M, Niu J, Lewis C, Torner J, Guermazi A, et al. Fluctuation of knee pain and changes in bone marrow lesions, effusions, and synovitis on magnetic resonance imaging. Arthritis Rheum. 2011;63(3):691\u20139.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"687_CR30","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/art.21290","volume":"52","author":"GH Lo","year":"2005","unstructured":"Lo GH, Hunter DJ, Zhang Y, McLennan CE, Lavalley MP, Kiel DP, et al. Bone marrow lesions in the knee are associated with increased local bone density. Arthritis Rheum. 2005;52(9):2814\u201321.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"687_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.joca.2013.04.006","volume":"21","author":"T Lowitz","year":"2013","unstructured":"Lowitz T, Museyko O, Bousson V, Laouisset L, Kalender WA, Laredo JD, et al. Bone marrow lesions identified by MRI in knee osteoarthritis are associated with locally increased bone mineral density measured by QCT. Osteoarthr Cartil. 2013;21(7):957\u201364.","journal-title":"Osteoarthr Cartil"},{"issue":"6","key":"687_CR32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00223-004-0160-7","volume":"76","author":"EA Messent","year":"2005","unstructured":"Messent EA, Buckland-Wright JC, Blake GM. Fractal analysis of trabecular bone in knee osteoarthritis (OA) is a more sensitive marker of disease status than bone mineral density (BMD). Calcif Tissue Int. 2005;76(6):419\u201325.","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"687_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.semarthrit.2018.01.008","volume":"48","author":"GH Lo","year":"2018","unstructured":"\u2022\u2022 Lo GH, Schneider E, Driban JB, Price LL, Hunter DJ, Eaton CB, et al. Periarticular bone predicts knee osteoarthritis progression: data from the Osteoarthritis Initiative. Semin Arthritis Rheum. 2018;48(2):155\u201361 Provides information that periarticular health in knees in people with OA associate with loss of radiographic joint space over a relatively short time frame, therefore the periarticular bone could be a therapeutic target in OA.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"687_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00256-008-0446-3","volume":"37","author":"MS Taljanovic","year":"2008","unstructured":"Taljanovic MS, Graham AR, Benjamin JB, Gmitro AF, Krupinski EA, Schwartz SA, et al. Bone marrow edema pattern in advanced hip osteoarthritis: quantitative assessment with magnetic resonance imaging and correlation with clinical examination, radiographic findings, and histopathology. Skelet Radiol. 2008;37(5):423\u201331.","journal-title":"Skelet Radiol"},{"issue":"4","key":"687_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/art.1780220405","volume":"22","author":"L Flora","year":"1979","unstructured":"Flora L. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum. 1979;22(4):340\u20136.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"687_CR36","first-page":"1691","volume":"266","author":"CJ Dunn","year":"1993","unstructured":"Dunn CJ, Galinet LA, Wu H, Nugent RA, Schlachter ST, Staite ND, et al. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther. 1993;266(3):1691\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"687_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0928-0987(98)00065-7","volume":"8","author":"N Makkonen","year":"1999","unstructured":"Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, et al. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci. 1999;8(2):109\u201318.","journal-title":"Eur J Pharm Sci"},{"key":"687_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/03009749509100906","volume":"101","author":"PL van Lent","year":"1995","unstructured":"van Lent PL, Holthuysen AE, van den Bersselaar L, van Rooijen N, van de Putte LB, van den Berg WB. Role of macrophage-like synovial lining cells in localization and expression of experimental arthritis. Scand J Rheumatol Suppl. 1995;101:83\u20139.","journal-title":"Scand J Rheumatol Suppl"},{"issue":"3","key":"687_CR39","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/jpet.102.035295","volume":"302","author":"J Wood","year":"2002","unstructured":"Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302(3):1055\u201361.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"687_CR40","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1002\/1529-0131(200108)44:8<1908::AID-ART329>3.0.CO;2-4","volume":"44","author":"A Ceponis","year":"2001","unstructured":"Ceponis A, Waris E, Monkkonen J, Laasonen L, Hyttinen M, Solovieva SA, et al. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum. 2001;44(8):1908\u201316.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"687_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1023\/B:IFLA.0000014707.49803.b6","volume":"28","author":"F Itoh","year":"2004","unstructured":"Itoh F, Aoyagi S, Kusama H, Kojima M, Kogo H. Effects of clodronate and alendronate on local and systemic changes in bone metabolism in rats with adjuvant arthritis. Inflammation. 2004;28(1):15\u201321.","journal-title":"Inflammation."},{"issue":"2","key":"687_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00011-003-1214-4","volume":"53","author":"H Harada","year":"2004","unstructured":"Harada H, Nakayama T, Nanaka T, Katsumata T. Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis. Inflamm Res. 2004;53(2):45\u201352.","journal-title":"Inflamm Res"},{"key":"687_CR43","first-page":"124","volume":"65","author":"A Corrado","year":"2017","unstructured":"\u2022\u2022 Corrado A, Maruotti N, Cantatore FP. Bisphosphonates and osteoarthritis. Journal of Gerontology and Geriatrics. 2017;65:124\u20139 Reviews the effects of bisphosphonates in OA and suggests that the they may determine some positive structural and symptomatic effects in the treatment of OA through different mechanisms including osteoclasts\/osteoblasts function, and inhibiting the synovial inflammation.","journal-title":"Journal of Gerontology and Geriatrics"},{"issue":"6","key":"687_CR44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.molmed.2008.04.001","volume":"14","author":"S Herman","year":"2008","unstructured":"Herman S, Kronke G, Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med. 2008;14(6):245\u201353.","journal-title":"Trends Mol Med"},{"issue":"3","key":"687_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/MJT.0b013e318247148f","volume":"19","author":"T Iannitti","year":"2012","unstructured":"Iannitti T, Rosini S, Lodi D, Frediani B, Rottigni V, Palmieri B. Bisphosphonates: focus on inflammation and bone loss. Am J Ther. 2012;19(3):228\u201346.","journal-title":"Am J Ther"},{"issue":"2","key":"687_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/ar148","volume":"3","author":"LJ Sandell","year":"2001","unstructured":"Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res. 2001;3(2):107\u201313.","journal-title":"Arthritis Res"},{"issue":"6","key":"687_CR47","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/art.1780400606","volume":"40","author":"A Okimura","year":"1997","unstructured":"Okimura A, Okada Y, Makihira S, Pan H, Yu L, Tanne K, et al. Enhancement of cartilage matrix protein synthesis in arthritic cartilage. Arthritis Rheum. 1997;40(6):1029\u201336.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"687_CR48","first-page":"2318","volume":"26","author":"FP Cantatore","year":"1999","unstructured":"Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol. 1999;26(11):2318\u201323.","journal-title":"J Rheumatol"},{"issue":"6","key":"687_CR49","first-page":"1117","volume":"23","author":"FP Cantatore","year":"1996","unstructured":"Cantatore FP, Introsso AM, Carrozzo M. Effects of bisphosphonates on interleukin 1, tumor necrosis factor alpha, and beta 2 microglobulin in rheumatoid arthritis. J Rheumatol. 1996;23(6):1117\u20138.","journal-title":"J Rheumatol"},{"issue":"9","key":"687_CR50","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/art.1780390915","volume":"39","author":"PL van Lent","year":"1996","unstructured":"van Lent PL, Holthuysen AE, van den Bersselaar LA, van Rooijen N, Joosten LA, van de Loo FA, et al. Phagocytic lining cells determine local expression of inflammation in type II collagen-induced arthritis. Arthritis Rheum. 1996;39(9):1545\u201355.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"687_CR51","first-page":"21","volume":"13","author":"AT Mehlhorn","year":"2008","unstructured":"Mehlhorn AT, Rechl H, Gradinger R, Stemberger A. Alendronate decreases TRACP 5b activity in osteoarthritic bone. Eur J Med Res. 2008;13(1):21\u20135.","journal-title":"Eur J Med Res"},{"issue":"2","key":"687_CR52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/rheumatology\/kel213","volume":"46","author":"JC Buckland-Wright","year":"2007","unstructured":"Buckland-Wright JC, Messent EA, Bingham CO 3rd, Ward RJ, Tonkin C. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford). 2007;46(2):257\u201364.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"687_CR53","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1002\/art.22160","volume":"54","author":"CO Bingham 3rd","year":"2006","unstructured":"Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006;54(11):3494\u2013507.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"687_CR54","doi-asserted-by":"publisher","first-page":"e72714","DOI":"10.1371\/journal.pone.0072714","volume":"8","author":"AJ Davis","year":"2013","unstructured":"Davis AJ, Smith TO, Hing CB, Sofat N. Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. PLoS One. 2013;8(9):e72714.","journal-title":"PLoS One"},{"issue":"3","key":"687_CR55","doi-asserted-by":"publisher","first-page":"R625","DOI":"10.1186\/ar1716","volume":"7","author":"TD Spector","year":"2005","unstructured":"Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Research & Therapy. 2005;7(3):R625\u201333.","journal-title":"Arthritis Research & Therapy"},{"issue":"12","key":"687_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023889","volume":"8","author":"LA Deveza","year":"2018","unstructured":"Deveza LA, Bierma-Zeinstra SMA, van Spil WE, Oo WM, Saragiotto BT, Neogi T, et al. Efficacy of bisphosphonates in specific knee osteoarthritis subpopulations: protocol for an OA Trial Bank systematic review and individual patient data meta-analysis. BMJ Open. 2018;8(12):e023889.","journal-title":"BMJ Open"},{"issue":"11","key":"687_CR57","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1002\/art.20627","volume":"50","author":"LD Carbone","year":"2004","unstructured":"Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 2004;50(11):3516\u201325.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"687_CR58","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2106\/JBJS.16.00385","volume":"99","author":"SH Fu","year":"2017","unstructured":"\u2022\u2022 Fu SH, Wang CY, Yang RS, Wu FL, Hsiao FY. Bisphosphonate use and the risk of undergoing total knee arthroplasty in osteoporotic patients with osteoarthritis: a nationwide cohort study in Taiwan. J Bone Joint Surg Am. 2017;99(11):938\u201346 Provides information that among patients with osteoporosis and osteoarthritis, bisphosphonate use was associated with a lower risk of total knee arthroplasty, and lower consumption of pain medications, especially for those with high adherence and longer treatment duration.","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"687_CR59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/annrheumdis-2017-211811","volume":"77","author":"T Neogi","year":"2018","unstructured":"\u2022\u2022 Neogi T, Li S, Peloquin C, Misra D, Zhang Y. Effect of bisphosphonates on knee replacement surgery. Ann Rheum Dis. 2018;77(1):92\u20137 Provides information that older bisphosphonates users women with incident knee OA had lower risk of knee replacement than nonusers of bisphosphonates, suggesting a potential beneficial effect of bisphosphonates on knee osteoarthritis.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"687_CR60","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s10067-017-3681-y","volume":"36","author":"G Saviola","year":"2017","unstructured":"\u2022\u2022 Saviola G, Abdi-Ali L, Povino MR, Campostrini L, Sacco S, Dalle Carbonare L, et al. Intramuscular clodronate in erosive osteoarthritis of the hand is effective on pain and reduces serum COMP: a randomized pilot trial-The ER.O.D.E. study (ERosive Osteoarthritis and Disodium-clodronate Evaluation). Clin Rheumatol. 2017;36(10):2343\u201350 Reviews informations that intramuscular clodronate is effective in the treatment of active painful erosive osteoarthritis of the hand. CLO is able to reduce pain and to decrease the pain-related disability, and could also play a role as a disease-modifying drug.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"687_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40268-020-00294-4","volume":"20","author":"B Frediani","year":"2020","unstructured":"\u2022\u2022 Frediani B, Toscano C, Falsetti P, Nicosia A, Pierguidi S, Migliore A, et al. Intramuscular clodronate in long-term treatment of symptomatic knee osteoarthritis: a randomized controlled study. Drugs R D. 2020;20(1):39\u201345 Provides information that intramuscular administrations of clodronate are effective in the management of symptomatic knee osteoarthritis, improving functional outcomes and reducing pain and bone marrow edema.","journal-title":"Drugs R D"},{"issue":"2","key":"687_CR62","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/art.41142","volume":"72","author":"SL Kolasinski","year":"2020","unstructured":"\u2022\u2022 Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheum. 2020;72(2):220\u201333 Guidelines that provides directions for clinicians and patients making treatment decisions for the management of OA. According to them, bisphosphonates are strongly recommended against in patients with knee, hip, and\/or hand OA.","journal-title":"Arthritis Rheum"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-021-00687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-021-00687-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-021-00687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:08:20Z","timestamp":1630706900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-021-00687-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s11914-021-00687-7","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"22 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MVV \u2013 no disclosures. CKK \u2013 Institutional grants from Abbvie, Lilly, Pfizer, GSK, Cumberland Pharmaceuticals; DSMB \u2013 Kolon Tissue Gene; Consulting \u2013 Regeneron, LG Chem, Express Scripts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}